大麻素与药物代谢动力学相互作用的风险解析
本文综述了大麻素(THC、CBD等)与神经痛、抑郁、焦虑、精神分裂症、癫痫及癌症治疗药物,以及他汀类、β受体阻滞剂、华法林、胰岛素类似物和二甲双胍等心代谢药物之间的药代动力学相互作用。文章指出大麻素可能通过影响ADME过程改变处方药暴露,需关注合并用药风险。
要点
- 大麻素与多种处方药存在潜在PK相互作用,涉及吸收、分布、代谢和排泄。
- 需特别关注大麻素与精神科药物及心代谢疾病治疗药物的合并使用。
- 临床应评估患者大麻使用情况以防范PK相关药物相互作用风险。
核心结论
- 大麻素与神经痛、抑郁、焦虑、精神分裂症、癫痫、癌症及心代谢疾病治疗药物之间存在潜在药代动力学相互作用,需引起临床重视。
研究设计与样本
- 本文为综合性综述,旨在批判性讨论主要大麻素与上述治疗药物之间的主要PK相互作用。
主要发现
- 大麻素可能通过改变处方药的吸收、分布、代谢和排泄过程而引发PK相互作用。
临床怎么用
- 临床在处方神经痛、精神疾病、癫痫、癌症及心代谢疾病治疗药物时,应主动询问患者大麻素使用情况并评估PK相互作用风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The relationship between cannabinoids and mental health has become a major focus of scientific inquiry and public discourse. Cannabinoids are diverse chemical compounds from the Cannabis species that have been explored for their therapeutic applications in treating chronic pain, psychiatric and neurological conditions, such as depression, schizophrenia, epilepsy and anxiety. Additionally, cannabinoids are frequently used for recreational purposes. The evolving legislation surrounding cannabis has added a layer of complexity to the understanding of its pharmacological effects. Societal attitudes shifting towards a more permissive acceptance of cannabis use make it essential to balance individual freedom with public health concerns. While the use of cannabinoids remains a subject of ongoing research, clinical data have shown promise in the treatment of mental health disorders. However, debates and concerns have been raised regarding the potential pharmacokinetic (PK) drug-drug interactions that may occur, involving changes in the absorption, distribution, metabolism and excretion (ADME) of the prescribed drugs. The future prospect of patients having unrestricted access to cannabis requires special attention in case of concurrent use with the common medical treatments they may be receiving for a cardiovascular or metabolic disease or with medications related to the treatment of psychiatric disorders. This comprehensive review aims to critically discuss the main PK interactions of major cannabinoids (tetrahydrocannabinol, cannabidiol, cannabinol, cannabichromene and cannabigerol) in relation to the drugs prescribed in neuropathic pain, depression, anxiety, schizophrenia, epilepsy and cancer, as well as with the most common cardiometabolic disease treatments such as statins, beta-blockers, warfarin, insulin analogues and metformin.
引用
- Papakyriakopoulou P, Valsami G, Ismailos G, et al. Cannabinoids and drug-drug pharmacokinetic interactions: Deciphering the risks. Br J Clin Pharmacol. 2026. PMID: 41633759. doi:10.1002/bcp.70430
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。